TMIC — Last-Resort Antimicrobial MIC Testing
The BioMaxima Targeted MIC Strip (TMIC) applies the established gradient diffusion principle to a curated panel of last-resort and difficult-to-treat antimicrobial agents. Where standard broad-spectrum panels test routine susceptibility, the TMIC panel targets agents reserved for extensively drug-resistant (XDR) and pan-drug-resistant (PDR) organisms — carbapenems, novel beta-lactam combinations, polymyxins, and agents with recognised methodological limitations.
Critical agent-specific disclosures apply to colistin, polymyxin B, tigecycline, daptomycin, and fosfomycin. These are detailed in the IFU and summarised in the FAQ section below. Refer to current EUCAST guidance before applying gradient diffusion for these agents in clinical decision-making contexts.
TMIC strips are placed on Mueller-Hinton agar inoculated with the test organism. After 16–20 hours at 35 ± 1°C, the MIC is read at the ellipse/strip intersection. No serial dilution required. Note: fosfomycin requires G6P supplement. Colistin, tigecycline, and daptomycin require BMD confirmation for clinical decisions.
Results are interpreted using the current annual edition of EUCAST Clinical Breakpoint Tables or CLSI M100, classifying isolates as S (susceptible), I (susceptible at increased exposure), or R (resistant).
Why BioMaxima TMIC Strips
Developed through university research partnerships and a patented composite substrate — delivering consistent, reproducible gradient diffusion AST.
Biomedical Composite Carrier
TMIC strips use BioMaxima's patented biomedical composite carrier — delivering precise, consistent diffusion for last-resort agents across all 15 two-fold dilution steps. Reproducibility is critical when narrow MIC thresholds determine last-resort therapy selection.
University-Validated Technology
The MIC test platform was developed through a five-year research programme (2017–2022) in collaboration with UMCS Lublin (Departments of Genetics and Microbiology, and Biochemistry) and the Medical University of Lublin — with two patent applications filed as a result.
EUCAST & CLSI Aligned
TMIC gradients are calibrated against EUCAST and CLSI reference MIC distributions for last-resort agents. Agent-specific EUCAST guidance notes apply — see FAQ for colistin, tigecycline, daptomycin, and fosfomycin disclosures.
No Serial Dilution Required
For most TMIC agents, no serial dilution preparation is required. However, for colistin and polymyxin B, EUCAST recommends BMD as the reference method — gradient diffusion values for these agents must be confirmed by BMD before guiding therapy decisions.
Standard Laboratory Infrastructure
TMIC testing uses standard laboratory equipment for most agents. Results in 16–20 hours. Agent-specific notes: fosfomycin requires G6P-supplemented MHA; daptomycin may require calcium-supplemented MHA — refer to the IFU.
Supports AMR Stewardship
Quantitative MIC values in µg/mL support PK/PD-guided dose optimisation, enabling clinicians and stewardship pharmacists to tailor antibiotic regimens — supporting responsible antimicrobial use and contributing to the reduction of antimicrobial resistance.
TMIC Targeted Panel — Last-Resort Agents
The TMIC panel covers last-resort and difficult-to-treat agents. ⚠ denotes agents with EUCAST-recognised gradient diffusion limitations. Contact Advanced Biotech for the current full agent list and catalogue numbers.
Pack Sizes
TMIC strips are individually packaged per agent. Contact Advanced Biotech for pricing, catalogue numbers, and current availability.
Suitable for low-throughput testing, evaluation, or infrequent use of specific agents. Individually packaged strips maintain stability and reduce waste.
EnquireStandard pack size for routine clinical laboratory use. Cost-effective for regular AST workflows without requiring bulk storage of high-volume packs.
EnquireHigh-volume pack for reference laboratories, high-throughput clinical settings, or institutions requiring bulk supply of frequently tested agents.
EnquireTechnical Specifications
Key technical parameters for the TMIC Targeted MIC Test Strip. Agent-specific limitations apply — refer to IFU.
| Parameter | Specification |
|---|---|
| Product name | BioMaxima Targeted MIC Strip (TMIC) |
| Platform | Gradient diffusion minimum inhibitory concentration (MIC) test |
| Target organisms | Aerobic and facultatively anaerobic bacteria (routine clinical isolates) |
| Antibiotic coverage | Broad panel — major antibacterial agent classes (contact Advanced Biotech for current full list) |
| Dilution range | 15 two-fold dilution steps — factory-calibrated continuous gradient |
| Test medium | Mueller-Hinton agar (standard formulation, EUCAST/CLSI specification) |
| Inoculum | 0.5 McFarland turbidity standard — direct colony suspension method |
| Incubation temperature | 35 ± 1°C |
| Incubation duration | 16–20 hours (refer to IFU for organism-specific conditions) |
| MIC reading | µg/mL — read at ellipse/strip intersection point |
| Breakpoint standards | EUCAST Clinical Breakpoint Tables (current edition) / CLSI M100 |
| Pack sizes | 10, 30, 100 tests — individually packaged strips |
| Storage | 2–8°C (refer to product label and IFU) |
| Regulatory category | Class 2 IVD — for in vitro diagnostic use only |
| ARTG number | 524158 |
| Manufacturer | BioMaxima S.A., Lublin, Poland |
| Australian distributor | Advanced Biotech Pty Ltd |
Downloads
Instructions for Use, Safety Data Sheet, and regulatory documentation for TMIC Targeted MIC Test Strips.
Order TMIC or Request Technical Information
Contact Advanced Biotech Pty Ltd for pricing, catalogue numbers, pack sizes, and availability of TMIC Targeted MIC Test Strips in Australia.